Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCARB1 | Q8WTV0 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200829 | 0.75 | SCARB1 (0.62) | SCARB1 | |
| SCHEMBL4029839 | 0.66 | SCARB1 (0.67) | SCARB1 | |
| SCHEMBL13478790 | 0.64 | SCARB1 (0.47) | SCARB1 | |
| SCHEMBL13746591 | 0.63 | SCARB1 (0.52) | SCARB1 | |
| SCHEMBL13746604 | 0.62 | SCARB1 (0.62) | SCARB1 | |
| SCHEMBL26581388 | 0.62 | ACHE (0.46) | SCARB1 | |
| SCHEMBL4200388 | 0.61 | SCARB1 (0.73) | SCARB1 | |
| SCHEMBL4200984 | 0.61 | SCARB1 (0.68) | SCARB1 | |
| SCHEMBL13747782 | 0.61 | SCARB1 (0.66) | SCARB1 | |
| SCHEMBL7467529 | 0.60 | HTR6 (0.47) | SCARB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250057837-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-2970357-B1 | AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240232171-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2024-07-11 | — | — | US | disclosed |
| CN-107898790-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2024-06-21 | — | — | CN | disclosed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240115650-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240082245-A1 | Methods for Treating HCV | ABBVIE INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20230385268-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-4159795-A1 | THERAPEUTIC CONJUGATES WITH SULFATED DENDRIMERS FOR INTRACELLULAR TARGETING | ICD-Therapeutics GmbH (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-11484534-B2 | Methods for treating HCV | ABBVIE INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220288153-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288153-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | SCARB1 273/4885 |
| US-20250057837-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | SCARB1 240/4885 |
| US-20240115650-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | SCARB1 240/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCARB1 1274/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | SCARB1 3254/4885 |
| US-11484534-B2 | Methods for treating HCV | EIF2AK2, IFNAR1, IFNG | SCARB1 240/4885 |
| US-20240082245-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | SCARB1 240/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | SCARB1 4470/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | SCARB1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.